MBX Biosciences, Inc. (MBX) earnings date

Nasdaq · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 39 days, typically, give or take 16 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Mon, Nov 9, 2026after close 40 8-K
Q2 FY2026Thu, Aug 6, 2026before open 37 8-K
Q1 FY2026Thu, May 7, 2026during market hours 37 8-K
Q4 FY2025Thu, Mar 12, 2026before open 71 8-K
Q3 FY2025Thu, Nov 6, 2025before open 37 8-K
Q2 FY2025Thu, Aug 7, 2025before open 38 8-K
Q1 FY2025Mon, May 12, 2025before open 42 8-K
Q4 FY2024Mon, Mar 17, 2025before open 76 8-K

What they guided beta

Q3 FY2026 "Preclinical data for MBX 6180, a GLP-1/GIP/GCG triple agonist prodrug with potential for once-monthly dosing, accepted for presentation at ObesityWeek 2026 $481.6 million in cash and investments expected to support operations into 2029 CARMEL, Ind., and BURLINGTON, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the third quarter end" exhibit
Q3 FY2026 "12-week MAD (Part C) data for MBX 4291 on track for Q4 2026: Following initial Phase 1 data supporting the potential for once-monthly dosing, MBX remains on track to report unblinded data from the first cohort of the 12-week multiple ascending dose (MAD, Part C, Cohort 1) portion of its ongoing Phase 1 trial of MBX 4291." exhibit
Q3 FY2026 "Preclinical data for MBX 6180 accepted for presentation at ObesityWeek 2026: MBX expects to present preclinical pharmacokinetic data for MBX 6180, its GLP-1/GIP/GCG triple agonist prodrug designed for once-monthly dosing, in a poster presentation at ObesityWeek 2026, taking place November 14–17, 2026, in Washington, D.C." exhibit
Q3 FY2026 "Based on its current operating plan, the Company expects the combined cash, cash equivalents and marketable securities balance to fund operations into 2029." exhibit
Q3 FY2026 "Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the Company’s research and development activities; MBX Biosciences’ ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company’s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; MBX Biosciences’ ability to attract, " exhibit
Q2 FY2026 "Nomination of development candidate MBX 6180, a GLP-1/GIP/GCG triple agonist prodrug designed for once-monthly dosing, further expands obesity portfolio $418.6 million in cash and investments expected to support operations into 2029 CARMEL, Ind., and BURLINGTON, Mass., Aug. 6, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the second quarter ended " exhibit
Q2 FY2026 "Phase 3 trial of once-weekly canvuparatide now recruiting: MBX remains on track to initiate a Phase 3 pivotal trial of once-weekly canvuparatide in chronic hypoparathyroidism in Q3 2026." exhibit
Q2 FY2026 "The Company remains on track to report data from the first cohort of the 12-week MAD (Part C) in Q4 2026." exhibit
Q2 FY2026 "The Company expects to present preclinical data from MBX 6180 at a scientific meeting in the fourth quarter of 2026." exhibit
Q2 FY2026 "Based on its current operating plan, the Company expects the combined cash, cash equivalents and marketable securities balance to fund operations into 2029." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/MBX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/MBX

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

MBX earnings date badge

HTML

<a href="https://veritasdata.dev/company/MBX/"><img src="https://veritasdata.dev/embed/MBX.svg" alt="MBX earnings date" width="240" height="56"></a>

Markdown

[![MBX earnings date](https://veritasdata.dev/embed/MBX.svg)](https://veritasdata.dev/company/MBX/)

Script

<script async src="https://veritasdata.dev/embed/MBX.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/MBX"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.